<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381108</url>
  </required_header>
  <id_info>
    <org_study_id>2005-4373</org_study_id>
    <nct_id>NCT00381108</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Pomegranate Tablets on Enlarged Prostates</brief_title>
  <official_title>A Randomized, Double Blinded, Controlled Clinical Trial of Pomegranate Tablets vs Placebo: Effects on Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pomegranate Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jarrow Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic&#xD;
      Hyperplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed benign prostatic hyperplasia (BPH) will be recruited from the&#xD;
      urology clinic at UCI medical center for this study as indicated in section 4. Once&#xD;
      recruited, patients will be randomized into two groups - placebo and pomegranate tablets.&#xD;
&#xD;
      Prior to randomization, there will be a 6 week run-in period in which the basal parameters&#xD;
      will be established. The basal parameters include a complete history and physical exam&#xD;
      including an AUA symptom questionnaire and men's sexual health questionnaire, urine culture,&#xD;
      urinalysis, PSA, serum chemistry (sodium, potassium, chloride, bicarbonate, BUN, creatinine,&#xD;
      glucose), serum free testosterone, serum dihydrotestosterone, maximum urinary flow rate&#xD;
      (Qmax), post void residual bladder volume, and prostate volume measurement via Trans-rectal&#xD;
      ultrasound. Then patients will be randomized either to the study group or to the control&#xD;
      group using a random number generator. All of the study subjects will be counseled to take&#xD;
      one capsule daily in the morning and not to consume any other prostate supplements, or other&#xD;
      forms of medical or herbal therapy for BPH.&#xD;
&#xD;
      Patients will be asked to come in every 2 months for the following tests and questionnaires&#xD;
      to be administered:&#xD;
&#xD;
        1. AUA Symptoms Score sheet&#xD;
&#xD;
        2. Men's Sexual Health Questionnaire&#xD;
&#xD;
        3. Urine culture&#xD;
&#xD;
        4. Urinalysis&#xD;
&#xD;
        5. PSA&#xD;
&#xD;
        6. Serum chemistry (sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose)&#xD;
&#xD;
        7. Serum free testosterone&#xD;
&#xD;
        8. Serum 5-dihydrotestosterone&#xD;
&#xD;
        9. Maximum urinary flow rate (Qmax)&#xD;
&#xD;
       10. Post void residual check&#xD;
&#xD;
       11. Prostate volume measurement via Trans-rectal ultrasound&#xD;
&#xD;
      Maximum blood volume that will be drawn for each blood draw is 10 ml (2 table spoon), and the&#xD;
      maximum blood draws per patient is 3 per person if there is no crossover and 6 if there is a&#xD;
      crossover. Prior to all blood draw, patients will be asked to refrain from sexual intercourse&#xD;
      for at least 48 hrs.&#xD;
&#xD;
      Patients with severe BPH (AUA symptom score 20 and above) or those already on other forms of&#xD;
      medical therapy such as prescription finasteride, terazosin, or tamsulosin, propecia (for&#xD;
      hair loss) or have any history of prostate surgery are not eligible to participate in this&#xD;
      study. Also, patients who are taking non prescription supplements such as Saw Palmetto,&#xD;
      B-sitosterol, vitamin E, quercetin, will not be included in the study. One group (n = 10)&#xD;
      will take the pomegranate tablet. Group 2 (n = 10) will take 1 placebo tablet in the morning&#xD;
      daily. Both pomegranate tablets and placebo will be provided by the Pomegranate Health&#xD;
      Company.&#xD;
&#xD;
      Prior to randomization, there will be a 6-week run-in time because voiding parameters are&#xD;
      notoriously variable. During this run-in time, patients will be asked to return to clinic&#xD;
      every two weeks to measure maximum urinary flow and post-void residual bladder volume.&#xD;
&#xD;
      After a six-month period, each subject will be crossed over individually from placebo to&#xD;
      active treatment, and from active treatment to placebo. The total anticipated timeline for&#xD;
      the study is 12 months.&#xD;
&#xD;
      If early termination from the study is requested a final evaluation will be given. The final&#xD;
      evaluation of the study will entail a standard office visit with blood collection and final&#xD;
      AUA symptoms score and Men's sexual health questionnaire, and a transrectal ultrasound of the&#xD;
      prostate measuring the same parameters as in the previous office visits. Subsequently,&#xD;
      recommendations will be made by a urologist regarding the standard treatment options for BPH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients w/ BPH symptoms will be followed w/ AUA symptom questionnaires &amp; exams; in addition, urinary flow rate &amp; post void residual checks will be done to determine whether patients on pomegranate tablets have a reduction in symptoms.</measure>
    <time_frame>Time points in which data is collected are initial visit, two weeks, four weeks, and 2, 4, 6, 8, 10, and 12 months.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Pomegranate Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Two tablets, twice daily.</description>
    <arm_group_label>Placebo Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomegranate Tablet</intervention_name>
    <description>Two tablets, twice daily.</description>
    <arm_group_label>Pomegranate Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Clinically diagnosed with mild to moderate BPH (AUA symptom score &lt;20)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with severe BPH (AUA symptom score &gt;21)&#xD;
&#xD;
          -  Currently using any other forms of medical therapy, prescription finasteride,&#xD;
             terazosin, tamsulosin or propecia (for hair loss).&#xD;
&#xD;
          -  Prior Transurethral resection of the prostate (TURP).&#xD;
&#xD;
          -  Using non-prescription supplements such as Saw Palmetto, B-sitosterol, vitamin E, and&#xD;
             quercetin.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leland Ronningen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCIMC Department of Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine-Department of Urology</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>September 26, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2006</study_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Leland Ronningnen, MD</name_title>
    <organization>University of California, Irvine</organization>
  </responsible_party>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 19, 2011</submitted>
    <returned>May 12, 2011</returned>
    <submitted>August 16, 2011</submitted>
    <returned>September 19, 2011</returned>
    <submitted>September 19, 2011</submitted>
    <returned>October 25, 2011</returned>
    <submitted>November 15, 2011</submitted>
    <returned>December 19, 2011</returned>
    <submitted>January 4, 2012</submitted>
    <returned>February 2, 2012</returned>
    <submitted>June 25, 2013</submitted>
    <returned>July 31, 2013</returned>
    <submitted>January 27, 2021</submitted>
    <returned>February 16, 2021</returned>
    <submitted>June 11, 2021</submitted>
    <returned>July 2, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

